Cervical Cancer-Market Insights, Epidemiology and Market Forecast-2023- EU5

Publisher Name :
Date: 01-Nov-2016
No. of pages: 60
This report is available at upto 40% Discount. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Cervical Cancer- Market Insights, Epidemiology and Market Forecast-2023- EU5" Report provides marketed drugs information of Cervical Cancer. It has included historical and forecasted epidemiology and market size of the Cervical Cancer for Europe (Germany, Spain, France, Italy and United Kingdom) for 2013-2023. DelveInsight estimates that the therapeutic market size of Cervical Cancer in European (EU5) market is expected to grow at a Compound Annual Growth Rate of 0.019% and reach up to USD 109.8 million by 2023. The global market size of prophylaxis treatment for Cervical Cancer is expected to grow at a Compound Annual Growth Rate of 0.71% and reach up to USD 2210.9 Million by 2023.

Cervical Cancer needs to be focused more and more because it adversely affects younger women. It is the fourth most common cause of death among women. Cervical Cancer occurs due to the uncontrolled growth of healthy cells in cervix and forms cervical lesions. It spreads to other tissues such as vagina and uterus. Cervical Cancer is caused by inheritance of defects or mutation in genes. Cervical cancer is also caused due to the infection by the Human Papilloma Virus (HPV) which can infect cells on the surface of the skin and those lining the genitals, anus, mouth and throat, but not the blood or internal organs such as the heart or lungs.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

- Marketed information including available prescription drugs, its patent and exclusivity details.

- The Report also covers the detailed global historical and forecasted epidemiological data for EU5 (France, Germany, Italy, Spain and UK) from 2013-2023.

- It also provides Market size of Cervical Cancer for EU5 (France, Germany, Italy, Spain and UK from 2013 and forecasted Market size to 2023.

- The report will help in developing business strategies by understanding the trends shaping and driving the EU5 (France, Germany, Italy, Spain and UK) market size of the Cervical Cancer

- Identifying patient populations in the EU5 (France, Germany, Italy, Spain and UK) Cervical Cancer market to improve product design, pricing, and launch plans.

- To understand the future market competition in EU5 (France, Germany, Italy, Spain and UK), Cervical Cancer therapeutics market, as well as prophylaxis and Insightful review of the key market drivers and barriers.

Cervical Cancer-Market Insights, Epidemiology and Market Forecast-2023- EU5

Table of Contents

Report Introduction
Cervical Cancer Disease Overview
Types of Cervical Cancer
Staging of Cervical Cancer
Pathophysiology
Etiology
Risk Factors of Cervical Cancer
Diagnosisof Cervical Cancer
Epidemiology and Patient Population of Cervical Cancer
United Kingdom (UK)
Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2016-2023)
Germany (GE)
Historical Incident Cases of Cervical Cancer in Germany (GE) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Germany (GE) (2016-2023)
Italy (IT)
Historical Incident Cases of Cervical Cancer in Italy (IT) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Italy (IT) (2016-2023)
France (FR)
Historical Incident Cases of Cervical Cancer in France (FR) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in France (FR) (2016-2023)
Spain (SP)
Historical Incident Cases of Cervical Cancer in Spain (SP) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Spain (SP) (2016-2023)
Treatment Landscape
Treatment Algorithm
Treatment by Stages
Cervical Cancer Treatment Regimens
Current Unmet Needs
Cervical Cancer Emerging therapies Market Size
a) Bevacizumab (Avastin)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Avastin Historical Market Sales 2013-2015
Cost of therapy of Avastin
Cervical Cancer Prophylaxis Treatments
a) Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Cervarix Historical Market Sales 2012-2015
Cost of therapy of Cervarix
b) Gardasil/ Gardasil 9
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Gardasil Historical Market Sales 2012-2015
Cost of therapy of Gardasil
Pipeline Product (Phase III)
a) Z-100 (Ancer 20)
b) Axalimogene filolisbac or AXAL (ADXS11-001)
c) Gimeracil-Oteracil-Tegafur (S-1, TS-1)
Pipeline Product Analysis
Cervical Cancer Therapeutics Market in Europe5
Historical market size of United Kingdom (UK) (2013-2015)
Forecasted market size of United Kingdom (UK) (2016-2023)
Historical market size of Germany (GE) (2013-2015)
Forecasted market size of Germany (GE) (2016-2023)
Historical market size of Italy (IT) (2013-2015)
Forecasted market size of Italy (IT) (2016-2023)
Historical market size of France (FR) (2013-2015)
Forecasted market size of France (FR) (2016-2023)
Historical market size of Spain (SP) (2013-2015)
Forecasted market size of Spain (SP)(2016-2023)
Cervical Cancer Prophylaxis Treatment Global
Historical Prophylaxis treatment market size (2013-2015)
Forecasted Prophylaxistreatment market size (2016-2023)
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Table 2: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2016-2023)
Table 3: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Table 4: Forecasted Incident Cases of Cervical Cancer in Germany (2016-2023)
Table 5:Historical Incident Cases of Cervical Cancer in Italy (2013-2015)
Table 6: Forecasted Incident Cases of Cervical Cancer in Italy (2016-2023)
Table 7: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Table 8: Forecasted Incident Cases of Cervical Cancer in France (2016-2023)
Table 9: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Table 10: Forecasted Incident Cases of Cervical Cancer in Spain (2016-2023)
Table 11: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Table 12: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2016-2023)
Table 13: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Table 14: Forecasted Cervical Cancer Therapeutics Market in Germany (2016-2023)
Table 15: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Table 16: Forecasted Cervical Cancer Therapeutics Market in Italy (2016-2023)
Table 17: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Table 18: Forecasted Cervical Cancer Therapeutics Market in France (2016-2023)
Table 19: Historical Cervical Cancer Therapeutics Market in Spain (2013-2015)
Table 20: Forecasted Cervical Cancer Therapeutics Market in Spain (2016-2023)
Table 21: Historical Cervical Cancer prophylaxis treatment global (2013-2015)
Table 21: Forecasted Cervical Cancer prophylaxis treatment global (2016-2023)

List of Figures

Figure 1: Pathophysiology ofCervical Cancer, 2016
Figure 2:Risk Factors ofCervical Cancer, 2016
Figure 3: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Figure 4: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2016-2023)
Figure 5: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Figure 6: Forecasted Incident Cases of Cervical Cancer in Germany (2016-2023)
Figure7:Historical Incident Cases of Cervical Cancer inItaly (2013-2015)
Figure8: Forecasted Incident Cases of Cervical Cancer in Italy (2016-2023)
Figure9: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Figure10: Forecasted Incident Cases of Cervical Cancer in France (2016-2023)
Figure 11: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Figure 12: Forecasted Incident Cases of Cervical Cancer in Spain (2016-2023)
Figure 13:Treatment Algorithm forCervical Cancer, 2016
Figure 14:Treatmentfor patients with Stage IA1 of Cervical Cancer, 2016
Figure 15:Treatmentfor patients with Stage IA2 of Cervical Cancer, 2016
Figure 16:Treatmentfor patients with Stage IB1 of Cervical Cancer, 2016
Figure 17:Treatmentfor patients with Stage IB2 to Stage IVAof Cervical Cancer, 2016
Figure 18:Treatmentfor patients with Stage IVB of Cervical Cancer, 2016
Figure19: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Figure20: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2016-2023)
Figure21: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Figure22: Forecasted Cervical Cancer Therapeutics Market in Germany (2016-2023)
Figure 23: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Figure24: Forecasted Cervical Cancer Therapeutics Market in Italy (2016-2023)
Figure25: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Figure 26: Forecasted Cervical Cancer Therapeutics Market in France (2016-2023)
Figure27: Historical Cervical Cancer Therapeutics Market in Spain (2013-2015)
Figure 28: Forecasted Cervical Cancer Therapeutics Market in Spain (2016-2023)
Figure29: Historical Cervical Cancer prophylaxis treatment global (2013-2015)
Figure30: Forecasted Cervical Cancer prophylaxis treatment global (2016-2023)
  • Global Malignant Melanoma Drug Sales Market Report 2016
    Published: 05-Dec-2016        Price: US 4000 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Malignant Melanoma Drug Revenue, means the sales value of Malignant Melanoma Drug This report studies sales (consumption) of Malignant Melanoma Drug in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Bristol-Myers Squibb - Enzon Pharmaceuticals - Exeli......
  • Global Letrozole Market Professional Survey Report 2016
    Published: 02-Dec-2016        Price: US 3500 Onwards        Pages: 106
    Notes: Production, means the output of Letrozole Revenue, means the sales value of Letrozole This report studies Letrozole in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manuf......
  • Global Tamoxifen Sales Market Report 2016
    Published: 02-Dec-2016        Price: US 4000 Onwards        Pages: 106
    Notes: Sales, means the sales volume of Tamoxifen Revenue, means the sales value of Tamoxifen This report studies sales (consumption) of Tamoxifen in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Teva - Yangtze River Pharmaceutical Group - Chemische Fabrik Berg - PCAS - Suzho......
  • Global Thyroid Cancer Drug Sales Market Report 2016
    Published: 02-Dec-2016        Price: US 4000 Onwards        Pages: 105
    Notes: Sales, means the sales volume of Thyroid Cancer Drug Revenue, means the sales value of Thyroid Cancer Drug This report studies sales (consumption) of Thyroid Cancer Drug in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Abott Laboratories - Genzyme - Eisai - Pfizer - La......
  • Global Paclitaxel Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 01-Dec-2016        Price: US 3480 Onwards        Pages: 117
    Paclitaxel is a mitotic inhibitor used in cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it taxol.Paclitaxel is a white crystalline powder, odorless and tasteless. It is insoluble in water and soluble in chloroform, acetone and other organic solvents.Scope of the Report:This report ......
  • Global Capecitabine Sales Market Report 2016
    Published: 30-Nov-2016        Price: US 4000 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Capecitabine Revenue, means the sales value of Capecitabine This report studies sales (consumption) of Capecitabine in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Roche - Tecoland - ScinoPharm - Aarti Group - Cipla - Intas......
  • United States Malignant Melanoma Drug Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Malignant Melanoma Drug Revenue, means the sales value of Malignant Melanoma Drug This report studies sales (consumption) of Malignant Melanoma Drug in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - Enzon Pharmaceuticals - Exelixis - GlaxoSmithKline - Merck - Navidea Biopharmaceuticals......
  • Global Prostate Cancer Drugs Market 2016-2020
    Published: 29-Nov-2016        Price: US 2500 Onwards        Pages: 91
    Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other part......
  • Europe Lentinan Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 124
    Notes: Sales, means the sales volume of Lentinan Revenue, means the sales value of Lentinan This report studies sales (consumption) of Lentinan in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Ajinomoto - Elicityl - Nammex - Panjin Gerun Biotech - Golden Horizon B......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs